ArticleNature2025
Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial.Nature medicine · 2026Trial
- Barcoded oligonucleotide system (BOLT) for targeted organ delivery.Bioactive materials · 2027Article
- Therapeutics Beyond Delivery: Repurposed Drugs and Biologic Pathways.Current hypertension reports · 2026Review
- Ligand-Mediated Reprogramming Redirects Liver-Tropic Ionizable Lipid Nanoparticles for Lung-Selective mRNA Delivery.Angewandte Chemie (International ed. in English) · 2026Article
- Structural evolution of ionizable lipids for nucleic acid delivery.Nature reviews. Chemistry · 2026Review
- Next-generation experimental techniques for mRNA lipid nanoparticle evaluation and protein interaction analysis.Molecular therapy. Nucleic acids · 2026Article
- Isthmin-2 is a first-trimester predictor of preeclampsia and fetal growth restriction.Nature medicine · 2026Article
- Isthmin 2 could determine the early origins of preeclampsia and fetal growth restriction.Nature medicine · 2026Article
- Preparation of targeted lipid nanoparticles for precision nucleic acid delivery.Nature protocols · 2026Review
- Preparation of placenta-tropic mRNA lipid nanoparticles for pregnancy disorders.Nature protocols · 2026Review
- Circadian control of circulating tumour-derived extracellular vesicle secretion affects targeted therapy efficacy.Nature cell biology · 2026Article
- Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations.Journal of the American Society of Nephrology : JASN · 2026Review
- Lipid Nanoparticle Protein Coronas Arise through Lipoprotein Fusion Rather Than Shell-like Adsorption.Nano letters · 2026Article
- Enhancing Lipid Nanoparticle-Mediated Circular RNA and mRNA Expression in the Placenta through Inhibition of IFNAR-JAK-STAT Signaling.Nano letters · 2026Article
- Resolving Heterogeneity of Targeted Lipid Nanoparticles Through Solution-Based Biophysical Analyses.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Dual-Targeted Nanotherapy Restores Redox Homeostasis and Suppresses Uterine Hypercontractility for Effective Preterm Birth Intervention.Advanced healthcare materials · 2026Article
- Mechanisms of the Oral-Gut Microbiota Axis in Adverse Pregnancy Outcomes.Microorganisms · 2026Review
- LINC00607 facilitates endothelial VEGF-A receptor FLT1 splicing.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- The Use of Deep Learning in RNA Therapeutic Development.ACS nano · 2026Review
- DNA-directed assembly of multivalent lipid nanoparticles for targeted T cell gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
15 authors.
Kelsey L SwingleDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-8475-9206
Alex G HamiltonDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-9810-5630
Hannah C SaffordDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Hannah C GeislerDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Ajay S ThatteDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7372-8893
Rohan PalankiDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Amanda M MurrayDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0000-2124-351X
Emily L HanDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0009-0008-6276-7502
Alvin J MukalelDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Xuexiang HanDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-0011-5222
Ryann A JosephDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-0795-6094
Aditi A GhalsasiDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Mohamad-Gabriel AlamehDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-5672-6930
Drew WeissmanDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael J MitchellDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA. mjmitch@seas.upenn.edu.ORCID 0000-0002-3628-2244
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Maureen E. Murphy · 1985 to 2026
$75.9MA data-driven drug delivery (4D) platform for probing and treating the chemoresistant bone marrow microenvironmentDP2TR002776 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MITCHELL, MICHAEL J · 2018 to 2018
$2.4MmRNA lipid nanoparticles for pre-eclampsiaR01HD115877 · NICHD · UNIVERSITY OF PENNSYLVANIA · PI Michael J Mitchell · 2024 to 2026
$1.0MNCATS NIH HHS DP2 TR002776NCI NIH HHS P30 CA010815NICHD NIH HHS R01 HD115877
Abstract
Pre-eclampsia is a placental disorder that affects 3-5% of all pregnancies and is a leading cause of maternal and fetal morbidity worldwide
Indexed as
NanoparticlesPlacentaPre-EclampsiaRNA, MessengerVascular Endothelial Growth Factor AAnimalsDisease Models, AnimalFemaleLipidsLiposomesMaleMicePregnancyVascular Endothelial Growth Factor Receptor-1Lipid NanoparticlesLipidsLiposomesRNA, MessengerVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.